At what age do you start screening for depression with a Patient Health Questionnaire (PHQ-9)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Depression Screening with PHQ-9: Starting Age

Begin universal depression screening with the PHQ-9 at age 12 years, as endorsed by the U.S. Preventive Services Task Force (USPSTF) and supported by the American Academy of Pediatrics GLAD-PC guidelines. 1

Recommended Screening Age

  • The USPSTF clearly recommends universal adolescent depression screening starting at age 12 years and continuing through age 18 years. 1
  • This recommendation is based on evidence that validated depression screening tools exist for this age group and that effective treatments are available for identified patients. 1
  • The American Academy of Family Physicians and American Academy of Pediatrics align with this age 12 starting point. 2

Evidence Supporting Age 12 as the Starting Point

  • The PHQ-9 has been validated in adolescent primary care populations with a sensitivity of 89.5% and specificity of 77.5% at a cutoff score of 11 for detecting major depressive disorder. 1, 3
  • Most treatment trials demonstrating efficacy of SSRIs and psychotherapy were restricted to adolescents aged 12-14 years or older, providing the evidence base for intervention effectiveness in this age group. 1
  • The mean age of onset for major depressive disorder in childhood and adolescence is approximately 14-15 years, with onset earlier in girls than boys. 1

Considerations for Younger Children

  • Evidence for screening children younger than age 12 is insufficient, and the USPSTF does not recommend for or against screening in children aged 7-11 years. 4
  • Studies examining depression screening in younger populations (ages 8-14 years) typically include depression as part of broader psychosocial screening rather than focused depression screening. 1
  • No screening studies included children younger than age 11 years when the USPSTF evaluated the evidence. 1
  • The literature shows starting ages ranging from 8 to 14 years across various studies, but most depression-specific screening focuses on older age ranges. 1

Implementation Requirements

  • Screening should only be implemented when adequate systems are in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. 2, 4
  • The PHQ-9 Modified for Teens may be more appropriate when screening adolescents specifically. 3
  • Immediate referral to mental health specialists is required for severe cases (PHQ-9 score 15-27) or any indication of suicidal ideation on item 9. 3

Clinical Pitfalls to Avoid

  • Do not screen without having a clear protocol for managing positive screens, as screening alone without intervention does not improve outcomes. 1
  • Pay particular attention to item 9 of the PHQ-9, which assesses thoughts of self-harm, as this requires immediate action regardless of total score. 3
  • Consider using the PHQ-2 as an initial brief screen (cutoff ≥3), followed by the full PHQ-9 if positive, though this two-stage approach may miss some cases of suicidality that would be detected by the PHQ-9. 1, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Depression: Screening and Diagnosis.

American family physician, 2018

Guideline

Depression Screening and Management Approach

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Screening for depression.

American family physician, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.